EyeGate Pharmaceuticals, Inc. (EYEG)
|Net Income (ttm)||-8.38M|
|Trading Day||February 26|
|Day's Range||5.52 - 6.06|
|52-Week Range||3.20 - 8.18|
- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development -
WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products f...
EyeGate Pharma shares doubled on Monday morning following the news of its acquisition of Austria's Panoptes Pharma. Zacks earlier boosted its target on EYEG stock to $15 a share.
Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor
Investors Should Be Excited For EyeGate's Ocular Bandage
Eyegate: Speculative Buy For Their Better-Than-SOC Treatment In Corneal Wound Repair
Shares of EyeGate Pharmaceuticals Inc. rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a band...
Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) shares are trading higher after the company received FDA approval to initiate its follow-on pilot study for punctate epitheliopathies (PE).
EyeGate Pharmaceuticals, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wou... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2019, EYEG's revenue was $2.69 million, an increase of 62.54% compared to the previous year's $1.65 million. Losses were -$7.10 million, -34.36% less than in 2018.
According to 2 analysts, the average rating for EYEG stock is "Buy." The 12-month stock price forecast is 15.25, which is an increase of 169.91% from the latest price.